Background/Aims: Vitamin D deficiency is hypothesized to represent a risk factor in several neoplasms. The aim of this study was to determine whether serum 25-hydroxyvitamin D (25-OHvitD) deficiency represents a risk factor for neuroendocrine neoplasms (NENs) and can be associated with overall survival (OS) and progression-free survival (PFS). Methods: From 2010 to 2015, 138 patients with gastro- entero-pancreatic NENs (61 females; median age, 63 years) were included in the study. Serum 25-OHvitD levels, which were measured at baseline, were defined as deficient if ≤20 ng/mL. In such cases, 25-OHvitD supplementation was administered to the patients. The possible associations between 25-OHvitD levels and disease grading, staging, overall OS, and PFS were considered. Furthermore, the possible association between 25-OHvitD supplementation and PFS or OS was evaluated by Cox proportional hazards regression. Results: Median 25-OHvitD levels were 12.9 ng/mL (range 2-32); in detail, 94 patients (68%) had ≤20 ng/mL, with 46 cases (33%) having ≤10 ng/mL. An inverse correlation was observed between 25-OHvitD levels and OS (p = 0.03, rs = -0.18) and PFS (p = 0.01, rs = -0.22). At Cox proportional hazards regression, mortality was not related to 25-OHvitD levels; however, there was an association between 25-OHvitD supplementation and OS (p < 0.002). Conclusions: Vitamin D deficiency is highly prevalent among NEN patients. 25-OHvitD supplementation potentially plays an important role in the correction of 25-OHvitD values, and has an influence on the clinical outcome. However, further studies are needed to confirm this observation.

Keywords:
Vitamin D deficiency, Neuroendocrine neoplasms, Gastro-entero-pancreatic neuroendocrine tumors
1.
Davis CD, Dwyer JT: The “sunshine vitamin”: benefits beyond bone? J Natl Cancer Inst 2007;99:1563-1565.
2.
Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-1688S.
3.
Okereke OI, Singh A: The role of vitamin D in the prevention of late-life depression. J Affect Disord 2016;198:1-14.
4.
Cantorna MT, Zhu Y, Froicu M, Wittke A: Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80:1717S-1720S.
5.
Giovannucci E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005;16:83-95.
6.
Rosen CJ: Clinical practice. Vitamin D insufficiency. N Engl J Med 2011;364:248-254.
7.
Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guérin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A: Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010;9:709-715.
8.
Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C: Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470.
9.
Michos ED, Melamed ML: Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008;11:7-12.
10.
Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM: Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-314.
11.
Swales HH, Wang TJ: Vitamin D and cardiovascular disease risk: emerging evidence. Curr Opin Cardiol 2010;25:513-517.
12.
Zittermann A: Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92: 39-48.
13.
Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S: Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012;95:91-100.
14.
Leyssens C, Verlinden L, Verstuyf A: Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. Endocr Relat Cancer 2013;20:R31-R47.
15.
Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ: The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-357.
16.
Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D: Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 2003;80:49-62.
17.
Jacobs ET, Encinas Dominguez C, Thatcher ML, Haussler MR: Nuclear vitamin D receptor: structure-function, molecular control of gene transcription, and novel bioactions; in Feldman D, Pike JW, Glorieux FH (eds): Vitamin D, ed 2. Oxford, Elsevier Academic Press, 2005, pp 219-261.
18.
Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, Dunstan CR: Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res 2010;70:1835-1844.
19.
Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR, Holick MF: Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res 2012;32:727-731.
20.
Kovalenko PL, Zhang Z, Yu JG, Li Y, Clinton SK, Fleet JC: Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prev Res (Phila) 2011;4:1617-1625.
21.
Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW: Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence. J Cancer 2016;7:232-240.
22.
Fedirko V, Bostick RM, Goodman M, Flanders WD, Gross MD: Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case-control study. Am J Epidemiol 2010;172:489-500.
23.
Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulou A, Misirli G, Trichopoulos D, Berrino F, Vineis P, Panico S, Palli D, Tumino R, Ros MM, van Gils CH, Peeters PH, Brustad M, Lund E, Tormo MJ, Ardanaz E, Rodríguez L, Sánchez MJ, Dorronsoro M, Gonzalez CA, Hallmans G, Palmqvist R, Roddam A, Key TJ, Khaw KT, Autier P, Hainaut P, Riboli E: Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010;340:b5500.
24.
Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, Michaud DS, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Cochrane BB, Wactawski-Wende J, Chlebowski RT, Willett WC, Manson JE, Giovannucci EL, Fuchs CS: Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2012;21:82-91.
25.
Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM: Prediagnostic plasma 25-hydroxyvitamin D and pancreatic cancer survival. J Clin Oncol 2016;34:2899-2905.
26.
Hummel D, Aggarwal A, Borka K, Bajna E, Kállay E, Horváth HC: The vitamin D system is deregulated in pancreatic diseases. J Steroid Biochem Mol Biol 2014;144:402-409.
27.
Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY, De Clercq P, Vandewalle M, Bouillon R: Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 2000;60:2673-2679.
28.
Oades GM, Dredge K, Kirby RS, Colston KW: Vitamin D receptor-dependent antitumour effects of 1,25 dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 2002;90:607-616.
29.
Milliken EL, Zhang X, Flask C, Duerk JL, MacDonald PN, Keri RA: EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer. Cancer Lett 2005;229:205-215.
30.
Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G: Risk and protective factors for small intestine neuroendocrine tumours: a prospective case-control study. Neuroendocrinology 2016;103:531-537.
31.
Motylewska E, Gawronska J, Niedziela A, Melen-Mucha G, Lawnicka H, Komorowski J, Swietoslawski J, Stepien H: Somatostatin analogs and tumor localization do not influence vitamin d concentration in patients with neuroendocrine tumors. Nutr Cancer 2016;68:428-434.
32.
Pyo JH, Hong SN, Min BH, Lee JH, Chang DK, Rhee PL, Kim JJ, Choi SK, Jung SH, Son HJ, Kim YH: Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center. J Gastroenterol 2016;51:1112-1121.
33.
Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI: Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 2014;23:1406-1413.
34.
Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Riboli E, Hercberg S, Norat T: Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1003-1016.
35.
Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H: Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011;29:3775-3782.
36.
Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E: Vitamin D and prevention of colorectal adenoma: a metaanalysis. Cancer Epidemiol Biomarkers Prev 2008;17:2958-2969.
37.
Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev Med 2011;53:10-16.
38.
Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo JC, Goodman M, Kim AS, Robertson DJ, Rothstein R, Shaukat A, Seabrook ME, Summers RW: A trial of calcium and vitamin D for the prevention of colorectal adenomas. N Engl J Med 2015;373:1519-1530.
39.
Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS, Pan A, Johnson L, Crowe F, Hu FB, Franco OH: Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort studies and randomised intervention studies. BMJ 2014;348:g1903.
40.
Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA: Prevalence of serum Vitamin D deficiency and insufficiency in cancer: review of the epidemiological literature. Exp Ther Med 2011;2:181-193.
41.
Morton A, Hardy J, Morton A, Tapuni A, Anderson H, Kingi N, Shannon C: Vitamin D deficiency in patients with malignancy in Brisbane. Support Care Cancer 2014;22:2223-2227.
42.
Aguirre M, Manzano N, Salas Y, Angel M, Díaz-Couselo FA, Zylberman M: Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in Buenos Aires, Argentina. Arch Osteoporos 2016;11:4.
43.
Niv Y, Sperber AD, Figer A, Igael D, Shany S, Fraser G, Schwartz B: In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma. Cancer 1999;86:391-397.
44.
Fakih Mg, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY: Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis 2009;24:219-224.
45.
Johansson H, Odén A, Kanis J, McCloskey E, Lorentzon M, Ljunggren Ö, Karlsson MK, Thorsby PM, Tivesten Å, Barrett-Connor E, Ohlsson C, Mellström D: Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int 2012;23:991-999.
46.
Prescott J, Bertrand KA, Reid BM, Permuth-Wey J, De Vivo I, Cramer DW, Terry KL, Tworoger SS: Evidence of differential effects of vitamin D receptor variants on epithelial ovarian cancer risk by predicted vitamin D status. Front Oncol 2014;4:286.
47.
Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J: Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res 2008;10:R31.
48.
Wang K, Dong M, Sheng W, Liu Q, Yu D, Dong Q, Li Q, Wang J: Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. Histopathology 2015;67:386-397.
49.
Fiebrich HB, Van Den Berg G, Kema IP, Links TP, Kleibeuker JH, Van Beek AP, Walenkamp AM, Sluiter WJ, De Vries EG: Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther 2010;32:1398-1404.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.